|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.55 / 2.50|
Phase IIa Clinical Data Presented at the ASCO 2016 Genitourinary Cancers Symposium
New Data Demonstrate Supinoxin™ Dose Dependently Inhibits Tumor Cell Growth in a Preclinical Model of Triple Negative Breast Cancer
Interim Data Show Archexin is Well Tolerated at the Doses Tested to Date With Early Evidence of Anti-Tumor Activity Observed in a Phase IIa Clinical Study in Metastatic Renal Cell Carcinoma
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Interim Data Suggest Potential Clinical Activity of Supinoxin™ and RX-3117 Anti-Cancer Therapies
Supinoxin(TM) and RX-3117 Are Safe and Well Tolerated in Cancer Patients With Advanced and Metastatic Solid Tumors and Demonstrate Preliminary Evidence of Clinical Activity
Presentations at Recent Scientific Conferences Showcase Novel Anti-Tumor Properties of Rexahn Compounds
Program Will Provide Foundation for Filing an IND Application for Phase I Trial
These under-$10 stocks look poised to breakout out and trade higher from current levels.
New Data on RX-3117 and Supinoxin(TM) Substantially Increase Excitement Around These Programs in Scientific and Clinical Oncology Communities
Data Presented at 2015 American Association for Cancer Research (AACR) Annual Meeting
RX-3117 Antitumor Activity Correlates With UCK2 Enzymatic Activity
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.